Evidence map›Paper›PMID 38473381›Full record

ReviewCancers2024

Management of Adverse Events Associated with Pomalidomide-Based Combinations in Patients with Relapsed/Refractory Multiple Myeloma.

Omar Nadeem, Sikander Ailawadhi, Jack Khouri, Louis Williams, Donna Catamero, Kathryn Maples, Jesús Berdeja

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 1 country.

Omar NadeemDana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
Sikander AilawadhiDepartment of Hematology & Oncology, Mayo Clinic, Jacksonville, FL 32224, USA.
Jack KhouriDepartment of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH 44195, USA.
Louis WilliamsDepartment of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH 44195, USA.
Donna CatameroMount Sinai Hospital, New York, NY 10029, USA.
Kathryn MaplesDepartment of Pharmacy, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.ORCID 0000-0003-1075-0959
Jesús BerdejaGreco-Hainsworth Centers for Cancer Research, Tennessee Oncology, Nashville, TN 37203, USA.
Cleveland Clinic · USEmory University · USHarvard University · USMayo Clinic in Florida · USMount Sinai Hospital · USTennessee Oncology · US

Funding

Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple MyelomaP50CA186781 · NCI · MAYO CLINIC ARIZONA · PI Peter Leif Bergsagel · 2015 to 2026
$25.5M
Celgene, a Bristol-Myers Squibb company N/ANCI NIH HHS P50 CA186781
6 · The paper itself

Abstract

Multi-agent regimens incorporating immunomodulatory (IMiD

Indexed as

adverse eventscase studiescereblon E3 ligase modulator (CELMoD™) agentscombination therapyimmunomodulatory (IMiD®) agentsmanagementpomalidomiderelapsed/refractory multiple myelomasafetytreatment selection

Identifiers

PMID38473381
PMCPMC10930695
OpenAlexW4392354717

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.